Therapeutic endoscopy

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

The Inner Circle Acknowledges, David Chua, M.D., FASGE as a Distinguished Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Monday, October 30, 2023

OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • Dr. Chua pursued a Medical Degree from the University of Santo Tomas Faculty of Medicine and Surgery.
  • He is considered an expert in colonoscopy, liver, hepatitis, Crohns, and IBS and Therapeutic Endoscopy.
  • Board certified by the American Board of Internal Medicine-Internal Medicine, and Gastroenterology by the American Board of Internal Medicine- Internal Medicine and Gastroenterology.

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

Retrieved on: 
Monday, April 3, 2023

JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (“JGH”) in Montreal, Canada, which is an affiliated teaching hospital of McGill University, Faculty of Medicine.

Key Points: 
  • The study will primarily examine the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.
  • With the Alpha DaRT technology and our expertise in developing novel advanced endoscopic techniques, we are thrilled to offer patients with inoperable advanced pancreatic cancer an innovative therapeutic option.
  • We hope that the Alpha DaRT treatment will offer better outcomes to these patients with such a challenging disease.
  • We appreciate the unconditional support from Alpha Tau and the MCTRC who worked together to eliminate any barriers for opening this trial at our hospital and for securing a straightforward procedure for Alpha DaRT insertion into the pancreatic tumor.”

New Book by Capital Health Cancer Specialists Looks at Cutting-Edge Care Options

Retrieved on: 
Monday, January 3, 2022

"Patients with hepato-pancreato-biliary malignancies face enormous challenges that require a multidisciplinary team of providers to manage their care from diagnosis through treatment," said Dr. Cataldo Doria.

Key Points: 
  • "Patients with hepato-pancreato-biliary malignancies face enormous challenges that require a multidisciplinary team of providers to manage their care from diagnosis through treatment," said Dr. Cataldo Doria.
  • As medical director of the Capital Health Cancer Center, Dr. Doria oversees clinical operations including disease-specific clinical performance groups, clinical research, and cancer care advancements to ensure widespread access to the best possible patient care and outcomes.
  • Capital Health Cancer Center, located at Capital Health Medical Center - Hopewell, is the area's most advanced provider of cancer treatment delivered by some of the most experienced medical experts.
  • For more information about Capital Health Cancer Center, visit capitalhealth.org/cancer .

Palliare announces US FDA 510(k) clearance to extend the indications of its EVA15 insufflation technology for use in endoscopic surgery

Retrieved on: 
Thursday, July 15, 2021

Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.
  • EVA15 is the first insufflator of its kind to be brought to market which will allow intelligent leak-tolerant constant pressure insufflation during endoscopic surgery, features that EVA15 currently offers for laparoscopic and robotic surgery.
  • For complex, long or high leak therapeutic endoscopy procedures, current insufflation requires careful ongoing management by the endoscopist.
  • Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

PENTAX Medical Enters Into A Distribution Agreement With Mobile Aspects In The United States

Retrieved on: 
Thursday, September 17, 2020

MONTVALE, N.J., Sept. 17, 2020 /PRNewswire/ --PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today a distribution agreement with Mobile Aspects for its iRIScope software and iRIScope cabinets product line.

Key Points: 
  • MONTVALE, N.J., Sept. 17, 2020 /PRNewswire/ --PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today a distribution agreement with Mobile Aspects for its iRIScope software and iRIScope cabinets product line.
  • Under the terms of the agreement, PENTAX Medical will serve as a United States sales agent ofiRIScope software and iRIScope cabinets.
  • The iRIScope system from Mobile Aspects is a flexible endoscope tracking system that utilizes barcode and Radio-Frequency Identification (RFID).
  • We are delighted to partner with Mobile Aspects, an organization that echoes this devotion," said Gerald W. Bottero, Global President of PENTAX Medical.

SonoScape Flagship 4-LED equipped FHD Endoscopy System was seen in Live Demo at Conference "Endoscopy on Air"

Retrieved on: 
Friday, July 3, 2020

The event touched upon the full spectrum of diagnostic and therapeutic endoscopy through the live streaming of more than 50 cases.

Key Points: 
  • The event touched upon the full spectrum of diagnostic and therapeutic endoscopy through the live streaming of more than 50 cases.
  • SonoScape started as one of the top ultrasound manufacturers globally, but it refused to be limited by its own shadow.
  • Since the establishment of its endoscopy division in 2012, the company keeps up its incrediblyfast pace in product development.
  • The new 4-LED equipped HD-550 was used in two live demos of the marathonlike endoscopy Live conference.

United States Gastrointestinal Endoscopic Devices Procedure Numbers Report 2019

Retrieved on: 
Thursday, April 11, 2019

DUBLIN, April 11, 2019 /PRNewswire/ -- The "Gastrointestinal Endoscopic Devices Procedure Numbers - United States - 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 11, 2019 /PRNewswire/ -- The "Gastrointestinal Endoscopic Devices Procedure Numbers - United States - 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • GI endoscopy is one of the most widely performed medical procedures in the United States.
  • The majority of these procedures are screenings related to colon cancer or the removal of abnormalities from the GI tract.
  • This analysis includes gastrointestinal (GI) endoscopy, capsule endoscopy, virtual colonoscopy, stenting, dilation, tissue biopsy, polypectomy snare, specimen retrieval, foreign-body, hemostasis, enteral feeding tube placement, anti-reflux device implantation and Barrett's esophagus ablation procedures.

United States Gastrointestinal Endoscopic Device Market Report Suite 2019: A Collection of 13 Reports with Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2019

The "Gastrointestinal Endoscopic Device Market Report Suite - United States - 2019-2025 (Includes 13 reports)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Endoscopic Device Market Report Suite - United States - 2019-2025 (Includes 13 reports)" report has been added to ResearchAndMarkets.com's offering.
  • In 2018, the largest segment in the GI endoscopic device market was the GI endoscope market.
  • The majority of total GI endoscope unit sales consisted of colonoscopes used in the hospital setting, either at a designated endoscopy room or general surgery suite, with the balance being used in the outpatient centers.
  • The GI endoscopic device market includes GI endoscopes, capsule endoscopy, virtual colonoscopy software, stenting and dilation devices, endoscopic retrograde cholangiopancreatography (ERCP) devices, biopsy forceps, polypectomy snares, endoscopic ultrasound (EUS) needles, foreign-body and specimen removal devices, hemostasis devices, enteral feeding devices, anti-reflux devices and Barrett's esophagus ablation devices.